Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Head and Neck Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Liver Neoplasms 1Laryngeal Neoplasms 1Hypoxia 1Hypopharyngeal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

fluoromisonidazole 1Thoracotomy 1Thoracic Surgery, Video-Assisted 1TH 302 1Nitroglycerin 1NVP-BKM120 1Atovaquone 13-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 13-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypoxia × fluoromisonidazole × Thoracic × Clear all
NCT01213030 2012-09-25

Clinical Evaluation of the New Hypoxia Imaging Agent HX4

Siemens Molecular Imaging

Phase 1/2 Completed
12 enrolled
GastrointestinalHead & NeckThoracic

Hypoxia, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡